CD19 and lymphoma: CAR T cell therapy has revolutionized immunotherapy in the last decade with the successful establishment of chimeric antigen receptor (CAR)-expressing cellular therapies as an alternative treatment in relapsed and refractory (r/r) homogeneously CD19-positive leukemias and lymphomas [1,2,3].